• Have any questions?
  • +88-01714063309
  • info@bdix.net
SDNF-LogoSDNF-LogoSDNF-LogoSDNF-Logo
  • Home
  • About
  • Covid 19
  • Contact

WHO panel issues strong advice against hydroxychloroquine for Covid-19

  • Home
  • Blog
  • Covid 19 Global Global International Organisations Global International Organisations WHO
  • WHO panel issues strong advice against hydroxychloroquine for Covid-19
New US Covid-19 cases hit plateau after steep drops
March 2, 2021
UK rollout data on AstraZeneca shot should guide other countries: vaccine chief
March 2, 2021

WHO panel issues strong advice against hydroxychloroquine for Covid-19

March 2, 2021
Categories
  • Global International Organisations WHO
  • Global Media Resources News
Tags

Published in: The Business Standard
Date: 02 March, 2021

 

“The anti-inflammatory drug should not be used in the fight against the pandemic and is “not worthwhile” exploring in further research studies of possible Covid-19 treatments”

The drug hydroxychloroquine, once touted by Donald Trump as a pandemic “game-changer”, should not be used to prevent Covid-19 and has no meaningful effect on patients already infected, a World Health Organization expert panel said on Tuesday.

The anti-inflammatory drug should not be used in the fight against the pandemic, the WHO’s Guideline Development Group (GDG) expert panel wrote in the BMJ British medical journal, and is “not worthwhile” exploring in further research studies of possible Covid-19 treatments.

This “strong recommendation”, the experts said, is based on high-certainty evidence from six randomised controlled trials involving more than 6,000 participants both with and without known exposure to Covid-19.

Former US President Trump said last March that hydroxychloroquine could be a game-changer in the coronavirus pandemic. He also said he was taking it himself, even after the US medicines regulator, the Food and Drug Administration (FDA), advised that its efficacy and safety were unproven.

But the WHO’s experts said they now “judged that almost all people would not consider this drug worthwhile”.

“The panel considers that this drug is no longer a research priority and that resources should rather be oriented to evaluate other more promising drugs to prevent Covid-19,” they wrote.

The WHO noted in a statement that the recommendation is a so-called “living guideline” on potential drugs for Covid-19.

The guidelines, which can be updated as new evidence emerges, are designed to advise doctors and healthcare providers on managing the respiratory disease and help them make better decisions for patients.

Source: https://tbsnews.net/coronavirus-chronicle/who-panel-issues-strong-advice-against-hydroxychloroquine-covid-19-209611

Related posts

December 31, 2021

World braces for Omicron tsunami


Read more
December 12, 2021

South African doctors see signs omicron is milder than delta


Read more
December 8, 2021

Highly unlikely’ Omicron can fully dodge vaccine protection: WHO


Read more

Search

Recent Posts

  • 3 more cases of Omicron infections found
    January 1, 2022
  • World braces for Omicron tsunami
    December 31, 2021
  • A sudden spike: 7 Covid-19 deaths, 509 cases in 24 hours
    December 30, 2021
  • In Bangladesh: First Omicron cases detected
    December 12, 2021
  • Omicron-a variant of concern
    December 12, 2021

Images

  • In pictures: Life in the time of coronavirus
    October 29, 2020
  • COVID-19: Pictures, Bangladesh steps up precautionary measures as its migrant workers return home
    June 30, 2020
  • Garment workers return from a workplace as factories reopened
    May 4, 2020
  • In pictures: How Dhaka looks during lockdown
    April 29, 2020
  • In Pictures: The effects of coronavirus lockdown in Bangladesh
    April 13, 2020

Our Address

Sustainable Development Networking Foundation (SDNF)
Firoz Tower (14th Floor), 152/3-B Pantho Path, Green Road, Dhaka-1205

Hours
Sunday–Thursday: 10:00AM–6:00PM

Hotline 24h:

+88 017 14063309

© 2021 Sustainable Development Networking Foundation (SDNF). All Rights Reserved